INSIGHT MOLECULAR DIAGNOSTIC (IMDX) Stock Price, Forecast & Analysis
USA - NASDAQ:IMDX - US68235C2061 - Common Stock
IMDX Key Statistics, Chart & Performance
The current stock price of IMDX is 6.24 USD. In the past month the price increased by 60.41%.
IMDX Latest News, Press Relases and Analysis
IMDX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.19 | 387.16B | ||
| AMGN | AMGEN INC | 14.64 | 172.38B | ||
| GILD | GILEAD SCIENCES INC | 14.51 | 147.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.59 | 104.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.61 | 69.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 868.04 | 58.03B | ||
| INSM | INSMED INC | N/A | 40.10B | ||
| NTRA | NATERA INC | N/A | 27.39B | ||
| BIIB | BIOGEN INC | 9.29 | 22.80B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.01 | 20.30B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 36.45 | 15.11B |
Related stock screener links
About IMDX
Company Profile
Insight Molecular Diagnostics, Inc. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. The company is headquartered in Nashville, Tennessee and currently employs 46 full-time employees. The company went IPO on 2015-12-30. The firm's technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). The company is in the process of rebranding its VitaGraft assay (also known as VitaGraft Kidney), which is a lab developed test, under the name GraftAssureCore. The firm's transplant products include GraftAssureCore, GraftAssureDx, GraftAssureIQ. Its oncology products include DetermaCNI, DetermaIO, and OncoTIME. GraftAssureCore is a clinical blood-based solid organ transplantation monitoring test. GraftAssureIQ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. OncoTIME enables research on the tumor immune microenvironment.
Company Info
INSIGHT MOLECULAR DIAGNOSTIC
2 International Plaza Dr., Suite 510
Nashville TENNESSEE US
Employees: 46
Phone: 19494097600
INSIGHT MOLECULAR DIAGNOSTIC / IMDX FAQ
What does INSIGHT MOLECULAR DIAGNOSTIC do?
Insight Molecular Diagnostics, Inc. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. The company is headquartered in Nashville, Tennessee and currently employs 46 full-time employees. The company went IPO on 2015-12-30. The firm's technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). The company is in the process of rebranding its VitaGraft assay (also known as VitaGraft Kidney), which is a lab developed test, under the name GraftAssureCore. The firm's transplant products include GraftAssureCore, GraftAssureDx, GraftAssureIQ. Its oncology products include DetermaCNI, DetermaIO, and OncoTIME. GraftAssureCore is a clinical blood-based solid organ transplantation monitoring test. GraftAssureIQ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. OncoTIME enables research on the tumor immune microenvironment.
Can you provide the latest stock price for INSIGHT MOLECULAR DIAGNOSTIC?
The current stock price of IMDX is 6.24 USD. The price decreased by -4% in the last trading session.
Does INSIGHT MOLECULAR DIAGNOSTIC pay dividends?
IMDX does not pay a dividend.
What is the ChartMill technical and fundamental rating of IMDX stock?
IMDX has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the PE ratio for IMDX stock?
INSIGHT MOLECULAR DIAGNOSTIC (IMDX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.47).
What is the market capitalization of IMDX stock?
INSIGHT MOLECULAR DIAGNOSTIC (IMDX) has a market capitalization of 178.59M USD. This makes IMDX a Micro Cap stock.
IMDX Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to IMDX.
IMDX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IMDX. Both the profitability and financial health of IMDX have multiple concerns.
IMDX Financial Highlights
Over the last trailing twelve months IMDX reported a non-GAAP Earnings per Share(EPS) of -3.47. The EPS increased by 21.49% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -125.54% | ||
| ROE | -5775.68% | ||
| Debt/Equity | 0.48 |
IMDX Forecast & Estimates
10 analysts have analysed IMDX and the average price target is 5.53 USD. This implies a price decrease of -11.46% is expected in the next year compared to the current price of 6.24.
For the next year, analysts expect an EPS growth of 77.4% and a revenue growth 555.1% for IMDX